MRK Jan 2025 90.000 call
| Previous close | 24.25 |
| Open | 24.25 |
| Bid | 23.85 |
| Ask | 25.50 |
| Strike | 90.00 |
| Expiry date | 2025-01-17 |
| Day's range | 24.25 - 24.25 |
| Contract range | N/A |
| Volume | |
| Open interest | 179 |
- Business Wire
Merck to Hold First-Quarter 2023 Sales and Earnings Conference Call on April 27
RAHWAY, N.J., March 30, 2023--Merck to Hold First-Quarter 2023 Sales and Earnings Conference Call on April 27
- Reuters
India exempts import tax on pricey rare disease medicines
The Indian government said on Thursday it was providing a full exemption from basic customs duty for rare disease therapies and Merck & Co Inc's cancer therapy Keytruda when such medicines were imported for personal use. The government said in a statement that while some drugs such as treatments for spinal muscular atrophy or Duchenne muscular dystrophy are already exempted from customs duty, it had received many requests for relief from import tax for other rare disease drugs.
- Business Wire
FDA Converts to Full Approval Indication for KEYTRUDA® (pembrolizumab) for Certain Adult and Pediatric Patients With Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors
RAHWAY, N.J., March 29, 2023--FDA Converts to Full Approval Indication for KEYTRUDA for Certain Adult and Pediatric Patients With Advanced MSI-H or dMMR Solid Tumors
